Brief: Minerva Neurosciences Announces Update On Its New Drug Application (NDA) For Roluperidone
28/12/2022 13:04
Dec 28 (Reuters) - Minerva Neurosciences Inc NERV.O :
* MINERVA NEUROSCIENCES ANNOUNCES UPDATE ON ITS NEW DRUG
APPLICATION (NDA) FOR ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE
SYMPTOMS IN SCHIZOPHRENIA
* MINERVA- FOLLOWING TYPE A MEETING HELD ON NOV 30, FDA
CONFIRMED
THAT REFUSE TO FILE LETTER DATED OCT 14 REMAINS IN EFFECT FOR
NDA FOR ROLUPERIDONE
Source text for Eikon: ID:nGNX4FDW9J
Further company coverage: NERV.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Minerva Neurosciences
See all newsU.S. RESEARCH ROUNDUP-Cisco, Fox Corp, Target
Brief: Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates
Brief: Minerva Neurosciences - To Offer And Sell Up To $75 Million In Common Stock Through Leerink Partners
Brief: Minerva Announces Leadership Transition
Minerva Neurosciences Q4 net loss widens on non-cash financing charges